Although the use of digital health solutions for heart failure is increasing, few studies have demonstrated the impact of digital health solutions on public health systems worldwide. North America. Heart failure is on the rise, with 750,000 Canadians living with heart failure and more than 100,000 diagnosed each year.2 Heart failure is one of the main reasons why the following symptoms occur: Canada I’m hospitalized.2 By 2030, medical costs related to heart failure will be Canada is expected to reach $2.8 billion per year.2
A 3-month randomized controlled trial in heart failure outpatients at risk for hospitalization evaluated the CONTINUUM program versus standard treatment alone. This program included: 1. Self-care app via smartphone or tablet where patient enters vital signs, weight, and symptoms of heart failure. 2. Remote monitoring of these data by CHUM clinical nurses. 3. Digital therapy automatically sends medication suggestions to the treating medical team. 4. Heart failure education modules for patients – all based on Greybox Solutions’ Takecare platform.
Preliminary results show that the number of ER visits and/or hospitalizations (all causes) per patient was 0.19±0.47 in the intervention group and 0.55±0.89 in the control group (P=0.05). Survival analysis showed a trend favoring the intervention group (95 days (CI95% 87-104) vs. 78 days (CI95% 68-89); P=0.08). The total cost of medical consumption (hospitalization + emergency department visits) in the intervention group was $134,088 CAD vs. $174,924 CAD in control group (+30%).
“Given the prevalence and severity of heart failure symptoms, there is a real need for innovative solutions that can help improve patient outcomes and quality of life,” says Dr. Francois. Bernard Tournou, cardiologist at CHUM, associate professor at the University of Montreal, FRQS clinical researcher at the CHUM Research Center, and principal investigator of the trial. “The encouraging preliminary results of the CONTINUUM trial support further research to engage patients as partners in care and prevent serious heart failure events while reducing costs to the health care system.”
A total of 171 patients participated in the study. Preliminary results are available for the first 63 patients who completed the study, 32 in the intervention group (INT) and 31 in the control group (CTRL). Patients’ age (70 ± 12 years vs 69 ± 13 years), NYHA class (II 81 vs 87%), ejection fraction <40% (56 vs 48%), patients with comorbidities such as diabetes (38 vs 45%) , INT) were similar. vs. CTRL).
The CONTINUUM program is center Hospital of the University of Montreal (CHUM), CHUM Research Center, MEDTEQ+, Greybox Solutions Inc., Mitacs, PROMPT, and Boehringer Ingelheim (Canada) Ltd./Ltée. Boehringer Ingelheim (Canada) Ltd. had no role in the design or conduct of the study.
About CHUM
of center university hospital montreal (CHUM) is an innovative hospital dedicated to patients and patient service. quebec population. CHUM takes an integrated approach to health and population, which is reflected in all aspects of our mission, including care, education, research, management, innovation, and in our partnerships with patients and citizens (SERGIP). It is expressed. To achieve the goal of continuously improving population health, the management of patient care and life trajectories is being implemented using data analyzed by artificial intelligence from genetic and environmental information. CHUM collaborates with other speakers in the Health and Social Services Network (RSSS) to provide the best professional care and services, always based on the latest scientific knowledge. chumontreal.qc.ca
About Greybox Solutions Inc.
Greybox Solutions Inc. montrealis a healthcare technology company based in , and a pioneer in the development of digital therapy (DTx). Integrating numerous technologies within the versatile, accessible and innovative Takecare platform, Greybox provides cutting-edge solutions to many complex challenges at the heart of healthcare systems. Greybox Solutions, a developer of technology solutions that provide simple and dynamic alternatives for monitoring chronic diseases, has partnered with the Hospital Center Université de Montréal (CHUM) and Boehringer Ingelheim Canada to clinically develop its own demonstrated the effectiveness of the DTx solution. field of heart failure. Clinical applications are currently being evaluated in medical fields related to heart disease, lung disease, mental health, neonatal care, etc., among others. www.greybox.ca
About MEDTEQ+
MEDTEQ+ is a pan-Canadian consortium for industrial research and innovation in medical technology that aims to accelerate the development of innovative technology solutions that improve people’s health and quality of life. By bringing together the complementary skills of industry and institutional partners and healthcare providers, MEDTEQ+ supports the validation, integration into healthcare networks, commercialization, and regional and international activities of these technologies. MEDTEQ+ provides support, grants and investment services to innovative companies.Since then December 2022, MEDTEQ+ is also the lead partner of the envisAGE initiative, which aims to promote the AgeTech ecosystem and support the growth and expansion of companies in the AgeTech market. MEDTEQ+ is inter alia dependent on financial support from governments. quebec,government Canadathe private sector, and complementary partners that foster relationships between research and industry. www.medteq.ca
Boehringer Ingelheim (Canada)Co., Ltd
Boehringer Ingelheim is working on breakthrough treatments that change lives now and for generations to come. The company is a leading research-driven biopharmaceutical company that creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. With more than 53,000 employees, he serves more than 130 markets across his two business units, Human Pharma and Animal Health. Boehringer Ingelheim’s Canadian headquarters was established in 1972. montreal, quebec And now Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people company-wide. Canada.Learn more about www.boehringer-ingelheim.com/ca
SOURCE Boehringer Ingelheim Canada Ltd.
Further information: Media contact: Andrée-Anne Toussaint, Communications Advisor, Center Hospitalier Université de Montréal (CHUM), email: [email protected], Phone: 514 890-8000, ext. 23675. Anne Coffey, Corporate Communications, Boehringer Ingelheim (Canada) Ltd., email:[email protected]Phone: 416-526-5388
